Principia SGR Finances CheckMab and Its Anti-Cancer Patent with €10 Million - McDermott Will & Emery

Principia SGR Finances CheckMab and Its Anti-Cancer Patent with €10 Million

Overview


Ettore Scandale and Gianmarco Scialpi advised Italian venture capital operator Principia Sgr on making a 10 million euro loan through its Principia Health Fund to CheckMab, the new company founded by a spin-off of the Milan State University to improve cancer treatment by producing more selective and effective drugs.